Cell and Gene Therapy Virus Production

Optimize Recombinant AAV and Lentivirus Production

High yield, high quality, and high-efficiency virus production is essential for advancing the field of cell and gene therapy. Producing enough viral particles to treat a high dose, high prevalence disease poses significant challenges. Manufacturers are forced to scale out and scale-up, driving investment in both CapEx and labor. With Mirus Bio, there’s a better way.

Optimizing your transfection process with the TransIT®-AAViator and TransIT-VirusGEN^® Transfection Systems and RevIT AAV Enhancer can yield significant increases in titer while delivering improved virus quality in upstream cell culture. These step-change improvements may eliminate or reduce the need for scaling up and scaling out, achieving significant short term and long-term cost savings.

Mirus Bio
Transfection Reagent + Enhancers

Fewer reactors, less media, less DNA

Fewer production runs, less hands-on time

Efficient use of time and materials, higher profitability

Higher Titers and Percent Full Capsids

VirusGEN plus RevIT AAV enhancer outperformed polymer-only reagents in both titer and percent full capsids

Higher titers lead to significant cost savings and more patient doses

VirusGEN^® is the only transfection platform to incorporate proprietary polymer and lipid technology – which enables both high efficiency and productivity.

Reduction in cost per dose driven by titer increase with
VirusGEN transfection platform and RevIT AAV enhancer*

Double the number of doses from a 200L bioreactor

*Process conditions: 200L bioreactor run in GMP setting, 3M cells per mL, Reagent : DNA ratios per supplier recommendations RevIT AAV enhancer added post transfection Dose: 5E+14, AAV8